
    
      This study consists of the following three cohorts. Cohort 1; subjects converted from rHuEPO
      or DA to ASP1517, Cohort 2; subjects converted from rHuEPO or DA to DA, Cohort 3; subjects
      converted from epoetin beta pegol (CERA) to ASP1517. In Cohort 1 and 3, ASP1517 will be
      administered orally for 52 weeks. In Cohort 2, DA will be administered subcutaneously for 24
      weeks.
    
  